TY - JOUR
T1 - The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure
AU - Wolinsky, David
AU - Hendel, Robert
AU - Cerqueira, Manuel
AU - Gold, Michael
AU - Narula, Jagat
AU - Singh, Jagmeet
AU - Shaw, Leslee
AU - Thomas, Gregory
AU - Wazni, Oussama
AU - Farnum, Carolyn
N1 - Funding Information:
David Wolinsky has served as a consultant for Magellan Rx, a speaker for GE Healthcare, a speaker and consultant for Astellas, and participated in a Steering Committee with Adenosine Therapeutics. Robert Hendel has served as a consultant for Magellan Rx, a consultant and Speakers' Bureau participant for Astellas Pharmaceuticals, and as a consultant for Adenosine Therapeutics. Manuel D. Cerqueira has served as a consultant for Astellas Pharmaceuticals and FluoroPharma USA, participated in a Speakers Program with Astellas Pharmaceuticals, and has received grants from Perceptive Informatics Inc.. Michael Gold has engaged in consulting and research contracts with Boston Scientific, Medtronic, and St. Jude and has received Speakers Fees from Biotronik. Carolyn Farnum is an employee of Magellan Health/CDMI, which was contracted by GE Healthcare to produce this supplement. Jagmeet P. Singh has served as consultant and lecturer for St. Jude Medical, Medtronic, Sorin, and Boston Scientific and as consult for Respicardia, Cardioinsight, and Impulse Dynamics. Jagat Narula has served as lead author on an ADMIRE manuscript funded by GE Healthcare, received fees from GE Healthcare for MIBG training of their field force, and has received speaker fees from American Society of Echocardiography. Gregory S. Thomas has received a grant from General Electric Research. Leslee Shaw and Oussama have no financial relations to disclose.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.
AB - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.
UR - http://www.scopus.com/inward/record.url?scp=84944743128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944743128&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.09.014
DO - 10.1016/j.amjcard.2015.09.014
M3 - Article
C2 - 26454812
AN - SCOPUS:84944743128
VL - 116
SP - S1-S9
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
ER -